Jane Street
NKTR icon

Jane Street’s Nektar Therapeutics NKTR Stock Holding History

Jane Street’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.11M Sell
112,652
-105,685
-48% -$6.02M ﹤0.01% 2806
2025
Q4 		$9.23M Buy
+218,337
New +$12.2M ﹤0.01% 2416
2024
Q4 		– Sell
-6,098
Closed -$119K – 10181
2024
Q3 		$119K Buy
6,098
+2,032
+50% +$38.7K ﹤0.01% 8923
2024
Q2 		$75.6K Buy
4,066
+1,422
+54% +$30K ﹤0.01% 8824
2024
Q1 		$37K Sell
2,644
-6,566
-71% -$68.7K ﹤0.01% 8805
2023
Q4 		$78.1K Buy
9,210
+7,799
+553% +$59.1K ﹤0.01% 8670
2023
Q3 		$12.6K Sell
1,411
-50,705
-97% -$488K ﹤0.01% 8363
2023
Q2 		$450K Buy
52,116
+17,336
+50% +$185K ﹤0.01% 6479
2023
Q1 		$367K Buy
34,780
+24,638
+243% +$745K ﹤0.01% 6853
2022
Q4 		$344K Buy
10,142
+8,877
+702% +$430K ﹤0.01% 6783
2022
Q3 		$60K Sell
1,265
-1,139
-47% -$67.8K ﹤0.01% 8865
2022
Q2 		$137K Sell
2,404
-40,113
-94% -$2.53M ﹤0.01% 8474
2022
Q1 		$3.44M Buy
42,517
+23,458
+123% +$3.47M ﹤0.01% 3693
2021
Q4 		$3.86M Buy
19,059
+15,938
+511% +$3.46M ﹤0.01% 3264
2021
Q3 		$841K Sell
3,121
-1,732
-36% -$416K ﹤0.01% 6256
2021
Q2 		$1.25M Buy
4,853
+3,683
+315% +$1.02M ﹤0.01% 5337
2021
Q1 		$351K Sell
1,170
-2,585
-69% -$805K ﹤0.01% 7442
2020
Q4 		$958K Buy
3,755
+1,359
+57% +$351K ﹤0.01% 4737
2020
Q3 		$596K Buy
2,396
+432
+22% +$136K ﹤0.01% 4886
2020
Q2 		$682K Buy
1,964
+458
+30% +$143K ﹤0.01% 4617
2020
Q1 		$403K Sell
1,506
-2,961
-66% -$916K ﹤0.01% 3883
2019
Q4 		$1.45M Buy
4,467
+2,496
+127% +$724K ﹤0.01% 2312
2019
Q3 		$538K Buy
1,971
+1,530
+347% +$561K ﹤0.01% 3452
2019
Q2 		$235K Sell
441
-371
-46% -$186K ﹤0.01% 4515
2019
Q1 		$409K Sell
812
-1,801
-69% -$1.07M ﹤0.01% 3894
2018
Q4 		$1.29M Sell
2,613
-185
-7% -$112K ﹤0.01% 2226
2018
Q3 		$2.56M Sell
2,798
-19,652
-88% -$16.8M 0.01% 1644
2018
Q2 		$16.4M Buy
+22,450
New +$25.9M 0.04% 378
2018
Q1 		– Sell
-2,376
Closed -$3.06M – 5202
2017
Q4 		$2.13M Buy
+2,376
New +$1.41M 0.01% 1530
2017
Q2 		– Sell
-667
Closed -$235K – 4693
2017
Q1 		$235K Buy
+667
New +$150K ﹤0.01% 3703
2014
Q4 		– Sell
-1,486
Closed -$269K – 2848
2014
Q3 		$269K Buy
+1,486
New +$284K ﹤0.01% 1966
2013
Q4 		– Sell
-2,959
Closed -$464K – 2714
2013
Q3 		$464K Sell
2,959
-620
-17% -$115K 0.01% 1770
2013
Q2 		$620K Buy
+3,579
New +$549K 0.01% 1262

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jane Street's NKTR Position: Q1 2026 in Review

Jane Street reduced its Nektar Therapeutics (NKTR) stake by 48% in Q1 2026, selling an estimated $6.02M and leaving 112,652 shares worth $8.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Jane Street first reported a position in NKTR in Q2 2013 and has held it in 33 quarters since. The position peaked at $16.4M in Q2 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jane Street held 112,652 shares of Nektar Therapeutics worth $8.11M as of Q1 2026.
  • Jane Street sold 105,685 Nektar Therapeutics shares in Q1 2026, an estimated $6.02M.
  • Nektar Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2806 holding.
  • Jane Street first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 33 quarters since.
  • Jane Street's Nektar Therapeutics position peaked at $16.4M in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.